Contents of Volume 140 · 1998

Ainsworth K, Smith SE, Zetterström TSC, Pei Q, Franklin M, Sharp T: Effect of antidepressant drugs on dopamine D_1 and D_2 receptor expression and dopamine release in the nucleus accumbens of the rat 470
Ali SF → Itzhak Y
Allan AM → Engel SR
Altemus M → Greenberg BD
Amrein R → Dingemanse J
Armario A → Gómez F
Arros DM → Marley RJ
Arroyo M, Markou A, Robbins TW, Everitt BJ: Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous access to cocaine 331
Arts MPM, Bemelmans FFJ, Cools AR: Role of the retrorubral nucleus in striatally elicited orofacial dyskinesia in cats: effects of muscimol and bicuculline 150

Bakshi V → Swerdlow NR
Balfour DJK → Birrell CE
Balster RL → Wiley JL
Bareggi SR, Ferini-Strambi L, Pirola R, Smirne S: Impairment of memory and plasma flunitrazepam levels 157
Bemelmans FFJ → Arts MPM
Beninger RJ → Mallet PE
Benjamin J → Greenberg BD
Berendsen HHG → Gommans J
Berger M → Ebert D
Birrell CE, Balfour DJK: The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine 142
Bishop KI, Curran HV: An investigation of the effects of benzodiazepine receptor ligands and of scopolamine on conceptual priming 345
Black MD → Itzhak Y
Boer JA den → Pian KLH
Bonta T → Mattingly BA
Bouwknecht JA → Gommans J
Broekkamp CLE → Gommans J
Buffenstein A → Keck PJr

Cadle CD → Malin DH
Camí J → Farré M
Cason CR → June HL
Chen SHA → June HL
Cohen C, Perrault G, Sanger DJ: Preferential involvement of D_3 versus D_2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats 478
Conners CK → Levin ED
Cools AR → Arts MPM
Cowen PJ → Sargent PA
Croghan GA → Hurt RD
Croghan IT → Hurt RD
Curran HV → Bishop KI

Dale LC → Hurt RD
Dance ME → Wiley JL
Daoust M → Naassila M
Deutsch SI → Tizabi Y
Dhatt R → Wewers ME
Dingemanse J, Wood N, Guentert T, Øie S, Ouwerkerk M, Amrein R: Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects 164
d'Alche-Birée F → Naassila M
Durlach PJ: The effects of a low dose of caffeine on cognitive performance 116

Easterling KW, Holtzman SG: Comparison of the discriminative and antinociceptive effects of morphine and its glucuronide metabolites after central or systemic administration in the rat 91
Ebert D, Berger M: Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation 1
Engel SR, Lyons CR, Allan AM: 5-HT_3 receptor over-expression decreases ethanol self administration in transgenic mice 243
Eranti VS, Gangadhar BN, Janakiramaiah N: Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E 418
Evenden JL: The pharmacology of impulsive behaviour in rats IV: the effects of selective serotonergic agents on a paced fixed consecutive number schedule 319
Everitt BJ → Arroyo M
Everitt BJ → Weissenborn R

Fabre LF → Moltke LL von
Farré M, Terán M-T, Roset PN, Mas M, Torrens M, Camí J: Abuse liability of flunitrazepam among methadone-maintained patients 486
Feighner J → Keck PJr
Ferguson J → Keck PJr
Ferini-Strambi L → Bareggi SR
Flood JF, Uezu K, Morley JE: Effect of histamine H_2 and H_3 receptor modulation in the septum on post-training memory processing 279
Fogelman SM → Moltke LL von
Fowler SC, Liou J-R: Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not 81
Fox P → Phillips S
Franklin M → Ainsworth K
Franklin PH → Ishmael JE

Gangadhar BN → Eranti VS
Gasior M → Jaszyna M
Geyer MA → Krebs-Thomson K
Geyer MA → Swerdlow NR
Gibbens M → Mercer AJ
Glennon RA → Young R
Goldberg SR → Jaszyna M
Gómez F, Graugés P, Martín M, Armario A: The effect of chronic administration of antidepressants on the circadian pattern of corticosterone in the rat 127
Gomez-Dahl LC → Hurt RD
Gommans J, Bouwknecht JA, Hijzen TH, Berendsen HHG, Broekkamp CLE, Maes RAA, Olivier B: Stimulus properties of fluvoxamine in a conditioned taste aversion procedure 496
Goutopoulos A → Järbe TUC
Granda BW → Moltke LL von
Grassi JM → Moltke LL von
Graugés P → Gómez F
Green TA → Miller DK
Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang S-J, Altemus M, Murphy DL: Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients 434
Greenblatt DJ → Moltke LL von
Grilly DM, Pistell PJ, Simon BB: Facilitation of stimulus detection performance of rats with *d*-amphetamine: a function of dose and level of training 272
Guentert T → Dingemanse J

Hacohen D → Pat-Horenczyk R
Hagan JJ → Hatcher JP
Harmatz JS → Moltke LL von
Harrigan EP → Keck PJr
Harris JA, Westbrook RF: Evidence that GABA transmission mediates context-specific extinction of learned fear 105
Hatcher JP, Hagan JJ: The effects of dopamine D_3/D_2 receptor agonists on intracranial self stimulation in the rat 405
Henricks KK → Marley RJ
Henry DJ, Hu X-T, White FJ: Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D_1 and D_2 receptor-selective agonists: relevance to cocaine sensitization 233
Herer P → Pat-Horenczyk R
Heyne A, Wolffgramm J: The development of addiction to *d*-amphetamine in an animal model: same principles as for alcohol and opiate 510
Hijzen TH → Gommans J
Himmler C → Mattingly BA
Hinton SC → Levin ED
Hitchcott PK, Phillips GD: Double dissociation of the behavioural effects of *R*(+) 7-OH-DPAT infusions in the central and basolateral amygdala nuclei upon Pavlovian and instrumental conditioned appetitive behaviours 458
Hitchcott PK, Phillips GD: Effects of intra-amygdala *R*(+) 7-OH-DPAT on intra-accumbens *d*-amphetamine-associated learning. I. Pavlovian conditioning 300
Hitchcott PK, Phillips GD: Effects of intra-amygdala *R*(+) 7-OH-DPAT on intra-accumbens *d*-amphetamine-associated learning. II. Instrumental conditioning 310
Holtzman SG → Easterling KW
Hu X-T → Henry DJ

Huang PL → Itzhak Y
Huang S-J → Greenberg BD
Hughes KM, Popi L, Wolgin DL: Experiential constraints on the development of tolerance to amphetamine hypophagia following sensitization of stereotypy: instrumental contingencies regulate the expression of sensitization 445
Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP: Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms 98

Ishmael JE, Franklin PH, Murray TF: Dextrorotatory opioids induce stereotyped behavior in Sprague-Dawley and Dark Agouti rats 206
Itzhak Y, Ali SF, Martin JL, Black MD, Huang PL: Resistance of neuronal nitric oxide synthase-deficient mice to cocaine-induced locomotor sensitization 378

Jaffe W → Keck PJr
Jäkälä P → Puoliväli J
Janakiramaiah N → Eranti VS
Järbe TUC, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A: Δ^9-THC training dose as a determinant for (*R*)-methanandamide generalization in rats 519
Jaszyna M, Gasior M, Shoaib M, Yasar S, Goldberg SR: Behavioral effects of nicotine, amphetamine and cocaine under a fixed-interval schedule of food reinforcement in rats chronically exposed to caffeine 257
Johnson SC → Malin DH
June HL, Cason CR, Chen SHA, Lewis MJ: Buprenorphine alters ethanol self-administration in rats: dose-response and time-dependent effects 29

Keck PJr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial 173
Keuler D → Greenberg BD
Koivisto E → Puoliväli J
Kramer SJ → Moltke LL von
Krebs-Thomson K, Geyer MA: Evidence for a functional interaction between 5-HT_{1A} and 5-HT_2 receptors in rats 69

Lake JR → Malin DH
Lamb RJ → Järbe TUC
Lamb RJ → Mercer AJ
Lavie P → Pat-Horenczyk R
Legrand E → Naassila M
Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE: Transdermal nicotine effects on attention 135
Lewis MJ → June HL
Lin S → Järbe TUC
Liou J-R → Fowler SC
Lyons CR → Engel SR

Mackee A → Rusted JM
Maes RAA → Gommans J
Makriyannis A → Järbe TUC
Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD: The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat 371
Mallet PE, Beninger RJ: The cannabinoid CB_1 receptor antagonist SR141716A attenuates the memory impairment produced by Δ^9-tetrahydrocannabinol or anandamide 11
March J → Levin ED
Markou A → Arroyo M
Marley ME → Marley RJ
Marley RJ, Arros DM, Henricks KK, Marley ME, Miner LL: Sensitivity to cocaine and amphetamine among mice selectively bred for differential cocaine sensitivity 42
Martin JD → Greenberg BD
Martin JL → Itzhak Y
Martín M → Gómez F
Mas M → Farré M
Mastropaolo J → Tizabi Y
Mattingly BA, Himmler C, Bonta T, Rice LL: Effects of selective dopamine D_1- and D_2-type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT 387
McMahon LR → Miller DK
Meck WH → Levin ED
Megen HJGM van → Pian KLH
Mercer AJ, Lamb RJ, Rolan PE, Gibbens M, Posner J: Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers 398
Miller DK, McMahon LR, Green TA, Nation JR, Wellman PJ: Repeated administration of ephedrine induces behavioral sensitization in rats 52
Miner LL → Marley RJ
Moltke LL von, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, Shader RI: Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects 293
Morgan D, Picker MJ: The μ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor 20
Morley JE → Flood JF
Morrissey MR → Keck PJr
Morutto SL → Phillips GD
Moss MC → Scholey AB
Moyer TP → Hurt RD
Mumenthaler MS, Taylor JL, O'Hara R, Yesavage JA: Influence of nicotine on simulator flight performance in nonsmokers 38
Murphy DL → Greenberg BD
Murray TF → Ishmael JE

Naassila M, Legrand E, d'Alche-Birée F, Daoust M: Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice 421
Nation JR → Miller DK

Offord KP → Hurt RD
Olivier B → Gommans J
O'Hara R → Mumenthaler MS
Ouwerkerk M → Dingemanse J
Øie S → Dingemanse J

Park CH → Tizabi Y
Pat-Horenczyk R, Hacohen D, Herer P, Lavie P: The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics 450
Pei Q → Ainsworth K
Perrault G → Cohen C
Phillips GD, Morutto SL: Post-session sulpiride infusions within the perifornical region of the lateral hypothalamus enhance consolidation of associative learning 354
Phillips GD → Hitchcott PK
Phillips S, Fox P: An investigation into the effects of nicotine gum on short-term memory 429
Pian KLH, Westenberg HGM, Megen HJGM van, Boer JA den: Sumatriptan (5-HT_{1D} receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder 365
Picker MJ → Morgan D
Picker MJ → Smith MA
Pirola R → Bareggi SR
Pistell PJ → Grilly DM
Popi L → Hughes KM
Posner J → Mercer AJ
Powell D → Tizabi Y
Puoliväli J, Jäkälä P, Koivisto E, Riekkinen P Jr: Oxotremorine suppresses thalamocortical oscillations via thalamic muscarinic acetylcholine receptors 285

Quested DJ → Sargent PA

Rice LL → Mattingly BA
Riekkinen P Jr → Puoliväli J
Riggs RL → Tizabi Y
Robbins TW → Arroyo M
Robbins TW → Weissenborn R
Robbins TW → Wit H de
Rolan PE → Mercer AJ
Rose JE → Levin ED
Roset PN → Farré M
Rosse RB → Tizabi Y
Rowlett JK, Spealman RD: Opioid enhancement of the discriminative stimulus effects of cocaine: evidence for involvement of μ and δ opioid receptors 217
Rusted JM, Mackee A, Williams R, Willner P: Deprivation state but not nicotine content of the cigarette affects responding by smokers on a progressive ratio task 411

Sanger DJ → Cohen C
Sargent PA, Quested DJ, Cowen PJ: Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT_2 receptors 120
Scholey AB, Moss MC, Wesnes K: Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory 123
Schweinle WE → Malin DH

Shader RI → Moltke LL von
Sharp T → Ainsworth K
Shenoi M → Malin DH
Shoaib M → Jaszyna M
Silva D → Levin ED
Simon BB → Grilly DM
Smirne S → Bareggi SR
Smith MA, Picker MJ: Tolerance and cross-tolerance to the rate-suppressing effects of opioids in butorphanol-treated rats: influence of maintenance dose and relative efficacy at the mu receptor 57
Smith SE → Ainsworth K
Spealman RD → Rowlett JK
Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA: Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats 75

Taaid N → Swerdlow NR
Taylor JL → Mumenthaler MS
Tejwani GA → Wewers ME
Terán M-T → Farré M
Tizabi Y, Mastropaolo J, Park CH, Riggs RL, Powell D, Rosse RB, Deutsch SI: Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications 202
Torrens M → Farré M

Uezu K → Flood JF
Upchurch TP → Malin DH

Waikar M → Swerdlow NR
Walker DJ, Zacny JP: Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers 191
Weissenborn R, Whitelaw RB, Robbins TW, Everitt BJ: Excitotoxic lesions of the mediodorsal thalamic nucleus attenuate intravenous cocaine self-administration 225
Wellman PJ → Miller DK
Wesnes K → Scholey AB
Westbrook RF → Harris JA
Westenberg HGM → Pian KLH
Wewers ME, Dhatt R, Tejwani GA: Naltrexone administration affects ad libitum smoking behavior 185
White FJ → Henry DJ
Whitelaw RB → Weissenborn R
Wiley JL, Dance ME, Balster RL: Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist 503
Williams R → Rusted JM
Willner P → Rusted JM
Wit H de, Robbins TW: Notice of Special Issue of Psychopharmacology: "Drugs and impulsivity: current theories, methods and results" 249
Wolffgramm J → Heyne A
Wolgin DL → Hughes KM
Wolter TD → Hurt RD
Wood N → Dingemanse J

Yasar S → Jaszyna M
Yesavage JA → Mumenthaler MS
Young R, Glennon RA: Discriminative stimulus effects of *S*(−)-methcathinone (CAT): a potent stimulant drug of abuse 250

Zacny JP → Walker DJ
Zetterström TSC → Ainsworth K

Indexed in *Current Contents, Psychological Abstracts, Psyc* INFO, *Index Medicus* and in *EMBASE*

Subject index of Volume 140 · 1998

A8 150
Abstinence 411
Abuse 206
Abuse liability 486
Acamprosate 421
Addiction 331, 510
Aerospace medicine 38
Agomelatine 503
Alcohol 510
Alcohol dependence 421
Alcohol drinking 243
Alcohol withdrawal 421
Amphetamine 42
D-Amphetamine 142
Amphetamine 257, 272, 445
Amygdala 300, 310, 354, 458
Analgesia 191
Anandamide 11, 519
Animal model 510
Antidepressant drug 470
Antidepressants 127
Antinociception 91
Antipsychotic drug 81
Antipsychotics 75
Antitussive 206
Anxiety 434
L-Arginine 371
D-Arginine 371
Attention 38, 135, 157
Aversive conditioning 279
Basolateral nuclei 458
Behavioral genetics 42
Behavioral sensitization 233, 387
Benzodiazepine 450, 486
Benzodiazepine inverse agonist 105
Benzodiazepines 345
Bicuculline 150
Buprenorphine 29
Butorphanol 57
Caffeine 116, 257
Cannabinoid 11
Cannabinoids 519
CANTAB 116
β-Carboline 105
311C90 398
Cat 150
Catalepsy 81
Central nucleus 458
Chewing gum 38
Chlorpromazine 75
Choice performance 272
Circadian rhythms 127
Clomipramine 120, 127
Clozapine 75
Cocaine 42, 52, 142, 217, 225, 233, 257, 378
Codeine 191
Cognition 38
Cognitive effects 411
Conceptual priming 345
Conditional discrimination 11
Conditioned reinforcement 331
Conditioned reward 310, 458
Conditioned taste aversion 496
Corticosteroid binding globulin 127
Cortisol 120
Craving 411
Cross tolerance 57
Cyamemazine 421
CYP2D1 206
Cytochrome P450 206
Cytochromes P450 293
D_2/D_3 dopamine receptors 478
D_3 receptor 300, 310, 458
d-Amphetamine 300, 310, 510
Dark Agouti 206
Dependence 57, 510
Depression 1
Desipramine 127
Dextromethorphan 206
Dextrorphan 206
Diazepam 503
Digit-span 123
Dizocilpine 202
DOI 69
Dopamine 1, 52, 250, 300, 310, 354, 421, 458
Dopamine agonist 478
Dopamine antagonist 478
Dopamine D_1 receptor 233
Dopamine D_1-type receptor 387
Dopamine D_2 receptor 233
Dopamine D_2-type receptor 387
Dopamine D_3 receptor 387
Dopamine receptor 81, 470
Double-blind 173
DPI (3,4 dihydroxy-phenylimino)-2-imidazoline 150
Drug discrimination 20, 91, 217, 250, 503, 519
Drug interaction 257
Drug-seeking 331
Efficacy 173, 519
Endogenous opioid peptides 185
Ephedrine 52

EPS 81
Ethanol 29
Ethanol self-administration 478
Explicit memory 157, 345
Extrapyramidal symptom 418
Fenfluramine 250
Fentanyl 217
FG 7142 105
Flumazenil 345
Flunitrazepam 157, 450, 486
Fluoxetine 434, 496
Fluvoxamine 496
GABA 150
Gepirone 293
Haloperidol 75, 250, 418
High dose 164
Histamine 279
5-HT_{1A} receptor 496
5-$HT_{1A/2}$ interaction 69
5-HT_2 receptor 120
5-HT_{2C} receptor 496
5-HT_3 receptor 243
5-HT_{1D} receptor agonist 365
5-HTP 120
Human 157, 191
Hyperoxia 123
Hypophagia 445
Imipramine 127
Implicit memory 345
Impulsivity 319
In situ hybridisation 470
Insomnia 450
Intracranial self-stimulation 405
Intrinsic efficacy 20
Irreversible antagonists 20
Isobologram 69
Ketamine 75
Knockout mice 378
Latent inhibition 105
Lateral hypothalamus 405
Locomotion 52
Locomotor activity 69, 142, 225, 378, 387
Lorazepam 398, 421
Loss of control 510
Match to sample 116
Mecamylamine 202
Mediodorsal thalamic nucleus 225
Melatonin 503
Memory 123, 279
Mesoaccumbens dopamine 142
Metergoline 434
Methadone 486
(*R*)-methanandamide 519
Methcathinone 250
Methoctramine 285
Methohexital 503
Mice 202, 279
Microdialysis 470
Migraine 5-$HT_{1B/1D}$ agonist 398
MK-801 202, 206
Moclobemide 164
Monkey 503
Mood 191
Mood state 185
Morphine 191
Morphine metabolites 91
Morphine-3-β-D-glucuronide 91
Morphine-6-β-D-glucuronide 91
Muscarinic acetylcholine receptor 285
Muscimol 150
Naltrexone 91, 185
Neocortical high-voltage spindles 285
Neuroleptics 81
Nicotine 38, 135, 142, 185, 202, 257, 411, 429
Nicotine blood level 98
Nicotine dependence 371
Nicotine gum 98, 429
Nicotine nasal spray 98
Nicotine skin patches 135
Nicotine withdrawal symptom 98
Nitric oxide 378
Nitric oxide synthase 371
NMDA 206
D-NNA 371
Non-match-to-position 11
Non-smoker 38
NOS 371
Nucleus accumbens 233, 300, 310, 470
Obsessive compulsive disorder 365, 434
8-OH-DPAT 69
7-OH-DPAT 310, 387, 458
(±)7-OH-DPAT 405
Opiate 191, 510
Opioid 57, 191
Opioid abuse 486
Opioids 20, 29, 91
Oral 191
Oro-facial dyskinesia 150
Over-expression 243
Oxotremorine 285
Oxyfree radicals 418
Oxygen 123
Pain 191
Pavlovian conditioning 300, 310, 354, 458
Perifornical region of the lateral hypothalamus 354
Pharmacodynamics 164
Pharmacokinetics 164
Phencyclidine 206
Phenelzine 127
Pigeons 20
Pituitary-adrenal axis 127
Placebo 173
Prefrontal cortex 225
Prepulse inhibition 75
Progressive ratio 411
Psychological therapy 450
Psychometric performance 398
Psychomotor 191
Psychomotor performance 38
Psychomotor sedation 157
Psychomotor stimulant 42
Psychostimulant 1
1-(2-Pyrimidinyl)-piperazine 293
Quinelorane 405
Quinpirole 233, 405
R(+) 7-OH-DPAT 300
Rat 29, 52, 57, 69, 81, 105, 250, 257, 272, 319, 405, 503, 510, 519
Reaction time 116
μ-Receptor 217
δ-Receptor 217
Receptor autoradiography 470
Reference memory 11
Reinforcement 185
Reinstatement 331
Relative efficacy 57
Retention 279
Retrorubral nucleus 150
Reward 225, 331, 405
S-20098 503
Schedule-controlled behavior 257
Schizoaffective 173
Schizophrenia 75, 173, 202
Scopolamine 345
Selective breeding 42
Self-administration 29, 225, 503
Sensitisation 142
Sensitization 52, 378, 445
Septum 279
Seroquel 75
Serotonin (5-HT) reuptake inhibitor 496
Serotonin agonist 319
Serotonin antagonist 319, 434
Serotonin reuptake inhibitor 434
Short-term memory 429
SKF 38393 233
Sleep deprivation 1
Smoking 185
SNC 80 217
Speedball 217
Squirrel monkey (*Saimiri sciureus*) 217
SR141716A 11
Stereotyped behavior 206
Stereotypy 445
Stimulant 331
Stimulants 250
Stimulus detection 272
Stimulus properties 496
Striatum 150
Subjective 191
Subjective experience 411
Substance abuse evaluation 503
Sulpiride 354
Sumatriptan 365
Symptom provocation 365
Task performance and analysis 38
Tea 116
Tetrahydroaminoacridine 285
Δ^9-tetrahydrocannabinol (Δ^9-THC) 11
Thalamocortical oscillations 285
Δ^9–THC 519
Therapy 1
Tolerability 164, 173
Tolerance 57, 445
Transdermal nicotine 135
Transgenic animal model 243
Ventral tegmental area 233
Vitamin E 418
Withdrawal 331, 450, 510
Withdrawal symptom 185
Working memory 11, 157
Workload 38
Ziprasidone 173
Zolmitriptan 398
Zopiclone 450